Skip to content

ILC Regulation Of Adaptive Immunity

Scope

This topic page organizes evidence that innate lymphoid cells regulate adaptive immunity, with emphasis on T cells, regulatory T cells, and B cells. It is written for the ILC-in-lung wiki, but the evidence base is deliberately tissue-labeled: the clearest direct lung anchors are ILC2 PD-L1 control of Th2 polarization, ILC2 OX40L control of local Th2/Treg expansion, and ILC2-Treg feedback through OX40L/OX40 and CCL1/CCR8-linked circuits in mouse type 2 inflammation, whereas much of the ILC3 evidence comes from gut, intestine-draining lymphoid tissue, tonsil, and blood.

Use this page when the question is "how can ILCs shape adaptive immune responses?" For lung disease claims, prioritize lung or airway sources and keep extrapulmonary mechanisms as context until pulmonary evidence is available.

Evidence tags

#cell/ILC2 #cell/ILC3 #cell/T_cell #cell/B_cell #cell/Treg #tissue/lung #tissue/gut #tissue/tonsil #axis/adaptive_immunity #axis/ILC_regulation

Confidence snapshot

Established observations

Lung ILC2 costimulation

  • ILC2s are not only cytokine producers. In mouse lung type 2 inflammation, IL-33 can induce OX40L on ILC2s, and ILC2-targeted OX40L loss impairs local adaptive type 2 inflammation after helminth or allergen challenge.
  • The adaptive cell partners in this source include Th2 cells and Tregs. This is currently the strongest lung-direct ILC-to-adaptive-immunity axis in the wiki.
  • Keep the species and perturbation context visible: this is mouse lung/adipose tissue evidence, not direct proof of human asthma therapeutic response.
  • PD-L1 adds a separate ILC2-to-Th2 checkpoint branch: in mouse N. brasiliensis infection, activated lung ILC2s use PD-L1 to engage PD-1 on CD4 T cells and promote GATA3 and IL-13, with conditional ILC-lineage Cd274 loss reducing adaptive Th2 output and worm clearance.
  • Newer OX40L/OX40 evidence turns the lung ILC2 costimulation branch into a feedback circuit: ILC2s support Gata3high Tregs, and Gata3high Tregs restrain effector-memory Th2 expansion by tuning OX40L availability on ILC2s.

ILC2-Treg feedback in lung type 2 inflammation

  • In mouse IL-33 and allergen lung models, Gata3high Tregs localize near ILC2-rich adventitial/peribronchovascular niches and depend on CCL1-CCR8 plus OX40L-OX40-linked dialogue for efficient local accumulation.
  • Treg-intrinsic OX40 loss reduces Gata3high Treg expansion and shifts the inflamed lung and mediastinal lymph node toward higher Th2/Treg ratios and effector-memory Th2 expansion.
  • This branch should be read as a local restraint circuit, not simply as ILC2 activation: ILC2-derived OX40L can support adaptive type 2 immunity, but Gata3high Tregs feed back to limit OX40L availability and cap the magnitude of the response.

ILC3 control of CD4 T-cell tolerance

  • MHCII-positive RORgammat-lineage ILCs and ILC3s can process/present antigen in gut-associated systems, but the observed output is restraint or selection of commensal-specific CD4 T cells rather than broad priming.
  • ILC3-intrinsic MHCII loss can unleash commensal-specific CD4 T-cell responses and intestinal inflammation in mouse models.
  • Human mucosal or pediatric IBD observations support relevance, but the tissue label remains gut.

ILC3 support and selection of Tregs

  • Intestinal ILC3-derived IL-2 can maintain local Tregs and oral tolerance downstream of macrophage/microbiota/IL-1beta cues.
  • LTi-like MHCII-positive ILC3s can select microbiota-specific RORgammat-positive Tregs and restrain inflammatory Th17 diversion through antigen presentation, alphaV integrin, and IL-2 competition.
  • ILC3-intrinsic CTLA-4 provides a separate gut checkpoint branch that restrains IL-23-mediated inflammatory T-cell programs (CTLA-4-expressing ILC3s restrain interleukin-23-mediated inflammation).

ILC3 help for regulatory B cells

  • Human CD40L-positive ILC3s can localize near B-cell regions in tonsil and support B-cell survival, proliferation, and IL-10-positive PD-L1-positive immature transitional regulatory B-cell differentiation in coculture.
  • The key molecular frame is CD40L, BAFF, and IL-15-linked crosstalk.
  • This is a human regulatory B-cell axis, but direct pulmonary compartment evidence is not yet present in this source set.

Context-dependent antigen presentation

  • ILC3 antigen-presentation biology can be tolerogenic, inflammatory, or tumor-immunity-linked depending on tissue context. Gut ILC3s often appear in tolerance circuits, CNS-infiltrating inflammatory ILC3s can restimulate pathogenic T cells, and colon-cancer ILC3-MHCII can support microbiota-linked type 1 immunity and anti-PD-1 responsiveness.
  • This context dependence is important for lung interpretation: detecting MHCII or antigen-presentation signatures in ILC-like cells would not by itself determine whether the output is tolerance, inflammation, or antitumor immunity.

Indirect tolerance and taxonomy boundaries

  • Gut ILC3s can also support adaptive tolerance indirectly through myeloid intermediates, including an ILC3-GM-CSF-myeloid regulatory circuit that is relevant to Treg-associated homeostasis (Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis).

  • Gut ILC3 regulation also depends on non-adaptive timing, metabolite, and neuroimmune inputs such as RANKL/RANK, circadian programs, FFAR2, VIP circuits, and trained defense states; these shape the conditions under which adaptive-tolerance mechanisms operate, but are not direct adaptive-cell mechanisms by themselves.

  • Intestinal ILC2-derived IL-10 adds a regulatory ILC2 state, but this is gut context and should not be converted into a default lung ILC2 claim (ILC2s are the predominant source of intestinal ILC-derived IL-10).

  • RORgammat-positive DCs are an ILC3-adjacent lineage-boundary issue for Treg homeostasis; this source should prevent over-attribution of RORgammat-positive antigen-presenting tolerance biology to ILC3s.

Review-level field frame

  • ILC-T-cell crosstalk can amplify effector immunity or restrain adaptive responses depending on tissue, subset, mediator, and timing.
  • For lung synthesis, use review sources to orient the reader and use primary sources for durable claims.

Mechanism maps

Lung anchor and gut T-cell tolerance

flowchart TB
    accTitle: ILC Adaptive Immunity T Cell Map
    accDescr: Compact map of lung ILC2 costimulation and gut ILC3 T-cell tolerance mechanisms.

    lung["Mouse lung"] --> pdl1["ILC2 PD-L1"]
    lung --> ilc2["ILC2 OX40L"]
    pdl1 --> th2_pol["Th2 polarization"]
    ilc2 --> th2["Th2 expansion"]
    ilc2 --> treg_lung["Gata3high Treg"]
    treg_lung -.-> ox40l_tune["OX40L tuning"]
    ox40l_tune -.-> th2
    gut["Gut / LN"] --> ilc3_mhcii["MHCII+ ILC3"]
    ilc3_mhcii --> cd4["CD4 restraint"]
    ilc3_mhcii --> treg_gut["Treg selection"]
    treg_gut --> tolerance["Tolerance"]

    classDef tissue fill:#e8f3ff,stroke:#3b6ea8,stroke-width:2px,color:#17324d
    classDef ilc fill:#fff4de,stroke:#b47a1f,stroke-width:2px,color:#4a3108
    classDef adaptive fill:#eef7ed,stroke:#4d8a50,stroke-width:2px,color:#173d1d
    class lung,gut tissue
    class pdl1,ilc2,ilc3_mhcii ilc
    class th2_pol,th2,treg_lung,ox40l_tune,cd4,treg_gut,tolerance adaptive

B-cell and checkpoint branches

flowchart TB
    accTitle: ILC Adaptive Immunity B Cell And Checkpoint Map
    accDescr: Compact map of human ILC3 regulatory B-cell help and gut ILC3 checkpoint restraint.

    tonsil["Human tonsil / blood"] --> cd40l["CD40L+ ILC3"]
    cd40l --> baff["BAFF / IL-15"]
    baff --> breg["IL-10+ Breg"]
    gut["Gut IL-23"] --> ctla4["CTLA-4+ ILC3"]
    ctla4 -.-> tcell["Inflammatory T cells"]
    breg --> restraint["Immune restraint"]
    tcell --> restraint

    classDef tissue fill:#e8f3ff,stroke:#3b6ea8,stroke-width:2px,color:#17324d
    classDef ilc fill:#fff4de,stroke:#b47a1f,stroke-width:2px,color:#4a3108
    classDef adaptive fill:#eef7ed,stroke:#4d8a50,stroke-width:2px,color:#173d1d
    class tonsil,gut tissue
    class cd40l,ctla4 ilc
    class baff,breg,tcell,restraint adaptive

Interpretation

ILC regulation of adaptive immunity should be modeled as a set of tissue-specific interfaces rather than as one universal function. In lung, the clearest current interfaces are ILC2 PD-L1 costimulation of Th2 polarization, ILC2 OX40L licensing of local type 2 adaptive immunity, and ILC2-Treg feedback that limits effector-memory Th2 expansion. In gut and mucosal lymphoid tissues, ILC3s can regulate CD4 T-cell tolerance, Treg maintenance/selection, and regulatory B-cell differentiation through MHCII, IL-2, alphaV integrin, CD40L, BAFF, IL-15, and CTLA-4-linked pathways.

The practical rule is to keep lung-direct evidence and extrapulmonary mechanism evidence in separate mental bins. Gut ILC3 tolerance biology is highly informative for how ILCs can shape adaptive immunity, but it should be cited as gut/mucosal context until matching lung, BAL, sputum, bronchial biopsy, or pulmonary lymph-node evidence is available.

Claim-level confidence boundaries

  • High confidence is used when the source directly tests an ILC-adaptive cell interaction in its stated tissue/model.
  • Medium-high confidence is used when human ex vivo, tissue-localization, or disease-association data support the axis but do not establish lung causality.
  • Medium confidence is used for review-level framing or cross-source synthesis.
  • Low confidence is used for direct pulmonary extrapolation from gut, tonsil, blood, or review-only evidence.

Future Expansion Directions

  • Add human lung, BAL, sputum, bronchial-biopsy, or pulmonary lymph-node data that directly test ILC regulation of T cells, B cells, or Tregs.
  • Separate ILC2-Th2/Treg costimulation from ILC3-MHCII/Treg tolerance mechanisms in future figures and grant text.
  • Track whether severe-asthma or infection datasets include paired ILC, T-cell, B-cell, and Treg state measurements with spatial or functional evidence.